Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH
16 sept. 2021 16h00 HE | INVENTIVA
Seven recruitments with solid track records and complementary profiles to reinforce Inventiva’s clinical expertise, medical team and corporate functions New recruitments further expand the Company’s...
Inventiva annonce des recrutements clés pour accélérer le développement de lanifibranor dans la NASH
16 sept. 2021 16h00 HE | INVENTIVA
Sept recrutements de profils expérimentés et complémentaires pour renforcer l’expertise clinique d’Inventiva, son équipe médicale et ses fonctions corporateCes recrutements permettent à la Société de...
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
16 sept. 2021 08h30 HE | ARCA biopharma, Inc.
First international patient enrolled in BrazilTrial approximately 75% enrolledrNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTopline trial data anticipated in...
MNPR Triangle 2.JPG
Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma
16 sept. 2021 08h00 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
logo.jpg
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
13 sept. 2021 05h00 HE | ImCheck Therapeutics SAS
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021 Marseille, France, September 13, 2021 – ImCheck Therapeutics today announced that it will present...
Inventiva’s 2021 First-Half Financial Results Presentation
10 sept. 2021 09h00 HE | INVENTIVA
Daix (France), September 10, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment...
Présentation des résultats financiers du 1er semestre 2021 d’Inventiva
10 sept. 2021 09h00 HE | INVENTIVA
Daix (France), le 10 septembre 2021 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale...
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
08 sept. 2021 16h00 HE | INVENTIVA
Activation of first clinical sites and start of patient screeningThe two-part NATiV3 Phase III clinical trial will evaluate the long-term efficacy and safety of lanifibranor in adult patients with...
Inventiva annonce le lancement de l’étude clinique pivot de Phase III évaluant lanifibranor dans la NASH
08 sept. 2021 16h00 HE | INVENTIVA
Ouverture des premiers sites cliniques et début du screening des patientsL’étude clinique de Phase III NATiV3 se déroulera en deux parties et évaluera l'efficacité et la tolérance à long terme de...
First-in-human clinical trial for a vaccine to treat opioid use disorders enrolls first patients
07 sept. 2021 08h30 HE | University of Minnesota Medical School
MINNEAPOLIS/ST. PAUL, Sept. 07, 2021 (GLOBE NEWSWIRE) -- The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use...